With three years to go, excitement and community engagement grow for LA28
06 June 2025 – With just over three years to go until…
BioAdaptives PawPa Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR Scale Improvements
LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives,…
GENESIS & CHOPARD UNITE IN CANNES LUXURY SHOWCASE
Genesis provides fleet of 30 cars to renowned luxury watch and jewellery…
VCTI Accelerates Service Provider Enterprise Sales With Broadband IQ
SOMERSET, N.J., May 14, 2025 /PRNewswire/ -- VCTI, the broadband expansion and…
FIS CrossCountry Committee reveals new Heat Mass Start format for Tour de Ski, and return of Holmenkollen 50km
May 13, 2025 - The main issue for the FIS Cross-Country Committee…
Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
May 07, 2025 17:45 ET | Source: Ashvattha Therapeutics Subcutaneous administration generally…
Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:…
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified…
Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36…
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…